AA induces ER stress, leading to transcriptional downregulation of the AR and suppression of PCa cell viability and proliferation. Targeting the PERK pathway may enhance AA efficacy in AR-driven PCa.

1 day ago

Journal

AR (Androgen receptor) • CASP3 (Caspase 3) • ATF4 (Activating Transcription Factor 4) • CASP7 (Caspase 7)

abiraterone acetate

Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review. (PubMed, Int J Mol Sci)

BRCA1/2-mutant patients benefited from Olaparib plus Abiraterone, while persistent alterations predicted early progression. We recommend unified reporting standards (e.g., variant allele frequency thresholds and panel composition) and prioritized prospective trials to validate high-impact targets. These steps will accelerate the integration of ctDNA into routine precision oncology practice worldwide.

8 days ago

Review • Journal • BRCA Biomarker • PARP Biomarker • Circulating tumor DNA

TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1)

Lynparza (olaparib) • abiraterone acetate

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC (clinicaltrials.gov)

P1/2, N=123, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

9 days ago

Enrollment open

Xtandi (enzalutamide) • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Abiraterone Acetate for Castrate Resistant Prostate Cancer (clinicaltrials.gov)

P=N/A, N=40, Completed, Massachusetts General Hospital | Active, not recruiting --> Completed

9 days ago

Trial completion

abiraterone acetate • prednisone

10d

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) (clinicaltrials.gov)

P1/2, N=203, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

10 days ago

Enrollment open

abiraterone acetate • Nubeqa (darolutamide) • tulmimetostat (DZR123)

10d

PRO-MIND: Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer (clinicaltrials.gov)

P=N/A, N=102, Recruiting, Ankara Etlik City Hospital | Not yet recruiting --> Recruiting

10 days ago

Enrollment open • HEOR

Xtandi (enzalutamide) • abiraterone acetate • Nubeqa (darolutamide) • apalutamide

10d

PRESTO: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (clinicaltrials.gov)

P3, N=504, Completed, Alliance Foundation Trials, LLC. | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Jun 2025

10 days ago

Trial completion • Trial completion date

abiraterone acetate • prednisone • bicalutamide • apalutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension

13d

MSTDM: Microsampling for Therapeutic Drug Monitoring of Oral Oncolytics in Oncology Patients (clinicaltrials.gov)

P=N/A, N=360, Recruiting, Leiden University Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Dec 2026 --> Dec 2027

13 days ago

Enrollment open • Trial completion date • Trial primary completion date

abiraterone acetate

13d

DB-1311-O-1001: A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)

P1/2, N=862, Recruiting, DualityBio Inc. | Trial completion date: Jan 2028 --> May 2028 | Trial primary completion date: Sep 2027 --> Dec 2027

13 days ago

Trial completion date • Trial primary completion date • First-in-human

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CD276 (CD276 Molecule)

BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12

Xtandi (enzalutamide) • abiraterone acetate • itraconazole • BNT324 • ritonavir

15d

OMAHA-004: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (clinicaltrials.gov)

P3, N=1314, Recruiting, Merck Sharp & Dohme LLC | Active, not recruiting --> Recruiting

15 days ago

Enrollment open

Xtandi (enzalutamide) • abiraterone acetate • prednisone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)

15d

Abiraterone/Prednisone + Standard ADT vs Standard ADT for Prostate Cancer Patients With PSMA-Positive Conventional Imaging Negative Pelvic Lymphadenopathy (clinicaltrials.gov)

P2, N=140, Not yet recruiting, University of Nebraska

15 days ago

New P2 trial

abiraterone acetate • prednisone

16d

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)

P1/2, N=100, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2026 --> Jun 2027 | Trial primary completion date: Sep 2025 --> Jun 2026

16 days ago

Trial completion date • Trial primary completion date

docetaxel • abiraterone acetate • prednisone • zeprumetostat (SHR-2554) • HRS-5041 • M9466